Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation

Nephrology Dialysis Transplantation

Volumn 25, Issue 1, 2010, Pages 283-292

  Fangmann, Josef ^a   Arns, Wolfgang ^b   Marti, Hans Peter ^c   Hauss, Johann ^a   Ketteler, Markus ^d   Beckurts, Tobias ^b   Boesmueller, Claudia ^e   Pohanka, Erich ^f   Martin, Pierre Yves ^g   Gerhardt, Moritz ^b   Farese, Stefan ^c   Neumayer, Hans H ^h   Floege, Juergen ⁱ   Gurr, Caroline ^b   Budde, Klemens ^h  

^a Universitaetsklinikum Leipzig   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d KLINIKUM COBURG   (Germany)

^e Universitaetsklinikum Koeln ^*  (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF GENEVA   (Switzerland)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cyclosporine; Daclizumab; Immunosuppression; Kidney; Transplantation

Indexed keywords

CORTICOSTEROID DERIVATIVE; CREATININE; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VIRUS INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOPSY; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 72949098594     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp468     Document Type: Article

References (35)

1. Fredericks S, Holt DW, MacPhee IA. The pharmacogenetics of im-munosuppression for organ transplantation: a route to individualiza-tion of drug administration. Am J Pharmacogenomics 2003; 3: 291-301
2. Nankivell BJ, Borrows RJ, Fung CL et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565
3. Webster A, Woodroffe RC, Taylor RS et al. Tacrolimus versus cy-closporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; 4: CD003961
4. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80(2 Suppl): S181-S190
5. Noorchashm H, Reed AJ, Rostami SY et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006; 177: 7715-7722
6. Sarwal MM, Vidhun JR, Alexander SR et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76: 1331-1339
7. Vincenti F, Kirkman R, Light S et al. Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165
8. Nashan B, LightS,Hardie IR et al. Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110-115
9. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 2005; 19: 39-46
10. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287
11. Vincenti F, Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol 2003; 14: 1940-1948
12. Ekberg H, Grinyó J, Nashan B et al. M. Cyclosporine sparing with my-cophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560-570
13. Ekberg H, Tedesco-Silva H, Demirbas A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
14. Kaplan B, Budde K. Lessons from the CAESAR Study: calcineurin inhibitors-can't live with them and can't live without them. Am J Transplant 2007; 7: 495-496
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
16. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723 (Pubitemid 29082898)
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481
18. Peto R, Peto J. Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc 1972; A135: 185-207
19. Fellström Cyclosporine nephrotoxicity. Transplant Proc 2004; 36(Suppl 2S): 220S-223S
20. Abramowicz D, Vanrenterghem Y, Squifflet JP et al. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicen-ter, prospective, pilot trial. Clin Transplant 2005; 19: 475-482
21. Smak Gregoor P et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365-1373
22. Dudley C, Pohanka E, Riad H et al. Mycophenolate Mofetil Creeping Creatinine Study Group. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the 'Creeping creatinine' study. Transplantation 2005; 79: 466-475
23. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655-662
24. Ingle GR, Moudgil A, Vo A et al. Cyclosporine-sparing effects of daclizumab in renal allograft recipients. Am J Health Syst Pharm 2005; 62: 391-396
25. Vincenti F, Friman S, Scheuermann E et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cy-closporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514
26. Poorrezagholi F, Einollahi B, Firoozan A et al. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation. Transplant Proc 2003; 35: 2735-2736
27. Rostaing L, Cantarovich D, Mourad G et al. CARMEN Study Group. Corticosteroid-free immunosuppression with tacrolimus, mycopheno-late mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814
28. ter Meulen CG, van Riemsdijk I, Hene RJ et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004; 4: 803-810
29. Light JA, Sasaki TM, Ghasemian R et al. Daclizumab induc-tion/tacrolimus sparing: a randomized prospective trial in renal transplantation. Clin Transplant 2002; 16(Suppl 7): 30-33
30. Kuypers DR, Evenepoel P, Maes B et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234-241
31. Wilson CH, Brook NR, Gok MA et al. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. Br J Surg 2005; 92: 681-687
32. Sanchez-Fructuoso AI, Marques M, Conesa J et al. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors. Transpl Int 2005; 18: 596-603
33. Sundberg AK, Rohr MS, Hartmann EL et al. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant 2004; 18 (Suppl 12): 61-66
34. Einecke G, Schütz M, Mai I et al. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 1463-1470
35. Nashan B, Bock A, Bosmans JL et al. Use of Neoral C monitoring: a European consensus. Transpl Int 2005; 18: 768-778